Freshfields advised Cartography Biosciences, Inc., a biotechnology company focused on advancing antibody-based cancer therapies, on its agreement with Pfizer pursuant to which Pfizer may option rights to exploit multiple tumor-selective antigens that Cartography will identify and validate through its proprietary ATLAS and SUMMIT discovery platforms.

Under the terms of the agreement, Cartography is eligible to receive up to $65 million in upfront, near-term milestone, and option exercise payments, and the agreement’s potential total deal value may exceed $850 million if all options are exercised, with Cartography being eligible to receive future development, regulatory, and commercial milestones and tiered royalties on net sales for any programs Pfizer advances under the collaboration.

The Freshfields team was led by partner Vinita Kailasanath and included senior associate Jake Silvers and associate Juliana Zhang.